¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ YhglL!p C  
,e$RvFB  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© `m1stK(PO  
;(,GS@ sP  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© X)]>E]X  
p=[dt  
1.Co-stimulators (or co-stimulating molecules) IuPDr %  
o+OX^F0  
2.NK-kB .Sw4{m[g  
N0lFx?4  
3.Immunoglobulin superfamily YVRE 9  
jyg>'"W  
4.antigen-presenting cell (APC) oIE(`l0l  
"AJ>pU3  
5.death domain Jp)PKS ![  
Jnt r"a-4  
6.CCR and CXCR -$s1k~o  
-{eiV0<^  
7.Lectin (or mitogen) /s)It  
_jkJw2+s\  
8.Clusters of differentiation, CD) ioTqT:.  
&U.y):  
9.B7 family ,,9vk\  
nYRD>S?uz  
10.Cytotoxic T lymphocyte, CTL) g5Hsz,x  
S9/\L6Rmf  
11.IL-15 and IL-15 receptor (IL-15R) P#A|Pn<p  
~;I{d7z,;  
12.MHC restriction i3Nt?FSN  
t.O4-+$ig  
13.Affinity-chromatography >273V+dy  
1^;&?E  
14.Cyctosprin A, CsA xi\uLu?i  
6B?1d /8V  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) v#IZSBvuQK  
Ox/va]e7"  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© v:j4#pEWD  
Sag\wKV8  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 tQ?}x#J  
':] w  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ b}q,cm  
aR;Q^YJ+a  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 b}G +7B  
X]CaWxM  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©  *JOv  
4]8PF  
ÃâÒßѧרҵ£º kQBVx8Uq]  
tv|=`~Y  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ J5rR?[i{  
_H3cqD  
Ïû»¯ÄÚ¿Æ£º ?,),%JQ  
 L_Ai/'  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ $S cjEG:6  
&k{@:z  
ѪҺ²¡Ñ§×¨Òµ£º B'0Il"g'  
(}qLxZ/U  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»